Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang-Xin Fu

Showing results (171-180 of 337) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2016
CTLA-4 Limits Anti-CD20-Mediated Tumor RegressionZhenhua Ren, Jingya Guo, Jing Liao, et al.
The Journal of Clinical Investigation|April 3, 2008
Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signalingSalvatore Papa, Francesca Zazzeroni, Yang-Xin Fu, et al.
Science (New York, N.Y.)|April 14, 2007
Lymphotoxin beta receptor-dependent control of lipid homeostasisJames C Lo, Yugang Wang, Alexei V Tumanov, et al.
Science Immunology|January 7, 2022
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumorsDiyuan Xue, Benjamin Moon, Jing Liao, et al.
Gut|October 31, 2022
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune toleranceChao-Yang Meng, Shiyu Sun, Yong Liang, et al.
Science Translational Medicine|August 5, 2021
Dual targeting of CTLA-4 and CD47 on T<sub>reg</sub> cells promotes immunity against solid tumorsAnli Zhang, Zhenhua Ren, Kuo-Fu Tseng, et al.
Cancer Research|February 9, 2011
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunityByron C Burnette, Hua Liang, Youjin Lee, et al.
Nature Biomedical Engineering|November 2, 2021
Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cellsLongchao Liu, Jiahui Chen, Joonbeom Bae, et al.
Nature Communications|July 9, 2024
Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacyHang Zhou, Wenjun Wang, Hairong Xu, et al.
Cancer Immunology Research|May 24, 2017
Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor RegressionJing Liao, Yan Luan, Zhenhua Ren, et al.
Pageof 34

Showing results (171-180 of 337) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2016
CTLA-4 Limits Anti-CD20-Mediated Tumor RegressionZhenhua Ren, Jingya Guo, Jing Liao, et al.
The Journal of Clinical Investigation|April 3, 2008
Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signalingSalvatore Papa, Francesca Zazzeroni, Yang-Xin Fu, et al.
Science (New York, N.Y.)|April 14, 2007
Lymphotoxin beta receptor-dependent control of lipid homeostasisJames C Lo, Yugang Wang, Alexei V Tumanov, et al.
Science Immunology|January 7, 2022
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumorsDiyuan Xue, Benjamin Moon, Jing Liao, et al.
Gut|October 31, 2022
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune toleranceChao-Yang Meng, Shiyu Sun, Yong Liang, et al.
Science Translational Medicine|August 5, 2021
Dual targeting of CTLA-4 and CD47 on T<sub>reg</sub> cells promotes immunity against solid tumorsAnli Zhang, Zhenhua Ren, Kuo-Fu Tseng, et al.
Cancer Research|February 9, 2011
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunityByron C Burnette, Hua Liang, Youjin Lee, et al.
Nature Biomedical Engineering|November 2, 2021
Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cellsLongchao Liu, Jiahui Chen, Joonbeom Bae, et al.
Nature Communications|July 9, 2024
Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacyHang Zhou, Wenjun Wang, Hairong Xu, et al.
Cancer Immunology Research|May 24, 2017
Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor RegressionJing Liao, Yan Luan, Zhenhua Ren, et al.
Pageof 34